-transparent.png){kind=logo}
A New Antihypertensive of the Imidazoline Series: 5-Fluoro-2-methyl-imidazolidinylidene-benzamine-monohydrochloride. 5-Fluoro-2-methyl-imidazolidinylidene-benzamine-hydrochloride (flutonidin, ST 600), a new antihypertensive imidazoline compound, was tested over 3 weeks in 20 patients with moderate to severe hypertension. Blood pressure was significantly lowered in both supine and upright position. In nearly 2/3 of the patients treated normalization of blood pressure was achieved. Side effects like sedation, dry mouth or orthostatic complaints were present in 30%. Toxic effects were not registered. It is recommended to reduce the dosage slowly especially in the aged to prevent, in part severe findings after abrupt withdrawal.
H Brunner, and
S Djawan, and
W Dorda, and
E Penner, and
G Grabner
March 1978,
Archiv der Pharmazie,
H Brunner, and
S Djawan, and
W Dorda, and
E Penner, and
G Grabner
January 1967,
Naunyn-Schmiedebergs Archiv fur experimentelle Pathologie und Pharmakologie,
H Brunner, and
S Djawan, and
W Dorda, and
E Penner, and
G Grabner
May 1983,
Minerva medica,
H Brunner, and
S Djawan, and
W Dorda, and
E Penner, and
G Grabner
May 1969,
Hospital (Rio de Janeiro, Brazil),
H Brunner, and
S Djawan, and
W Dorda, and
E Penner, and
G Grabner
July 1990,
Archives des maladies du coeur et des vaisseaux,
H Brunner, and
S Djawan, and
W Dorda, and
E Penner, and
G Grabner
February 1982,
International journal of clinical pharmacology, therapy, and toxicology,
H Brunner, and
S Djawan, and
W Dorda, and
E Penner, and
G Grabner
March 1958,
Canadian Medical Association journal,
H Brunner, and
S Djawan, and
W Dorda, and
E Penner, and
G Grabner
March 1989,
Journal of pharmaceutical sciences,
H Brunner, and
S Djawan, and
W Dorda, and
E Penner, and
G Grabner
August 1980,
The Medical journal of Australia,
H Brunner, and
S Djawan, and
W Dorda, and
E Penner, and
G Grabner
January 1985,
Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina,
